EGFR and lung adenocarcinoma: Therefore, we performed this multi-center retrospective study in R0-resected EGFR-mutant pathologic N2 lung adenocarcinoma to evaluate the optimal adjuvant systemic treatments and other prognostic factors of clinical outcomes.